Introduction
Cyclin-dependent kinase 8a nd cyclin C( CDK8/CycC) associate with the mediatorc omplexa nd regulate gene transcription of nearly all RNA polymerase II-dependentg enes. [1] [2] [3] [4] [5] An umber of studies have shown that CDK8/CycC modulates the transcriptional output from distinct transcription factors involved in oncogenic control, [6] which include the Wnt/b-catenin pathway, Notch, p53,a nd TGF-b. [7, 8] Compared with other CDKs, CDK8 is am ore gene-specific expression regulator [9, 10] and is differently expressed in cancer. [2] In this view,s elective inhibition of CDK8/ CycC could be apromising strategy for reducing mitogenic signals in cancer cells with decreased toxic effects on normal cells. [11, 12] The steroidal naturalp roduct cortistatin Ai st he first reported potent and selectivel igand of CDK8/CycC. [13] Inhibition of CDK8/CycCw ith cortistatin As uppresses acutem yeloid leukemia (AML) cell growth and has anticancer activityi n animal models of AML. [14] The existing ligands fall into two categories based on the major conformations of CDK8 to which they bind:T ype Il i-gands bind to the DMG-in( aspartate-methionine-glycine near the N-terminal region of the activation loop) conformationa nd occupy the ATP-binding site. The Senexin-type, CCT series, and COT series compounds,w hichp ossess4 -aminoquinazoline, [15] 3,4,5-trisubstituted pyridine, [16] and 6-azabenzothiophene [17] scaffolds, respectively,b elong to this category.S enex company researchers identified Senexin Bw ith an IC 50 value of 24 nm. Researcha nd development of new type IC DK8 ligandsh ave made significant progress in the past couple of years, and many promising compoundsh ave been identified. [18, 19] In 2016, new potent and selectiveC DK8 ligandsw ith ab enzylindazole scaffold, previously reported as heat-shockp rotein 90 ligands,w ere described by Schiemann etal. [20] One of the most promising molecules showeda nI C 50 value against CDK8/CycC of 10 nm.M ore recently, 4,5-dihydrothieno [3',4':3,4] benzo [1,2d] isothiazole derivatives were found to have sub-nanomolar potencyi nv itro (IC 50 :0 .46nm)a gainst CDK8/CycC as well as high selectivity. [21] Schneider et al. published the first pyrazoloureas eries of type II CDK8 ligands in 2013. [22] Type II ligands bind to the DMG-outc onformationa nd occupy the ATP-binding site and the allosterics ite (deep pocket). The deep pocket is adjacent to the ATP-binding site and is accessible in CDK8 by rearrangement of the DMG motif from the active (DMG-in) to the inactive state (DMG-out). This pocket is inaccessible in the DMG-in conformation, where the Met174 side chain is reoriented to make the site available to ATP. [23] Many well-known kinase ligands such as sorafenib and imatinib belongt ot he type II category.T he ligandsi dentified by Schneider et al. weref ound to anchori nt he CDK8 deep pocket andt oe xtend with diverse functional groups toward the hinge region and the front Selectivei nhibition of cyclin-dependentk inase 8a nd cyclin C (CDK8/CycC) has been suggested asapromising strategy for decreasing mitogenic signals in cancerc ells with reduced toxicity towardn ormalc ells. We developed an ovel virtual screening protocolf or drug developmenta nd applied it to the discovery of new CDK8/CycCtypeIIligands, whichisl ikely to achieve long residence time ands pecificity.W ef irst analyzed the binding thermodynamics of 11 published pyrazoloureal igands using molecular dynamics simulations and af ree-energy calculation method, VM2, and extracted the key binding information to assist virtual screening. The urea moietyw as found to be the criticalstructuralcontributor of the reference ligands. Start-ing with the urea moiety,w ec onducted substructure-based searches with our newly developed superposition ands inglepoint energy evaluation method, followed by free-energy calculations,a nd singled out three purchasablec ompounds for bioassayt esting. The ranking from the experimentalr esults is completely consistent with the predicted rankings. Ap otent drug-like compound was found to have a K d value of 42.5 nm, which is similar to those of the most potent reference ligands; this provided ag ood startingp oint forf urtheri mprovement. This study shows that our novel virtual screening protocoli s an accurate and efficient tool for drug development.
pocket. These variations can cause the ligandst oc hange from fast to slow binding kinetics, resultingi na ni mproved residence time, which is defined as the duration for whichaprotein is occupied by al igand. [24] As compared with type Il igands,b inding of at ype II compound to the DMG-out conformation often achieves longerr esidence time. [21, 22, 25, 26] Residence time is considered to be ak ey success factor for drug discoveryi na ddition to bindinga ffinity. [24, 27] Inspired by the discoveryo ft he pyrazolourea ligands, we furthered the research to discover new type II CDK8 ligands. We investigated the thermodynamics of the bindingb etween CDK8 and the 11 published type II ligands (Table 1) using ar igorous free-energy calculation methodw ith the VM2 software package. [28] The knowledge gained from our molecular dynamics (MD) simulations and free-energy calculations was then used with our recently developed substructure-based screen-ing protocol, followed by free-energy calculation to select tight binders. This paper is organized as follows:W ef irst presentt he analysis of binding free energies and the energy components of the 11 CDK8-ligandc omplexes with the help of both freeenergy calculations and MD simulations, from which we extract the key interactions as well as the mechanism in the binding between CDK8 andt he ligands. Then we present our substructure-based screening and free-energy calculation protocols, as illustrated in Figure 1a nd detailed in the Experimental Section below,f or compound selection, which is verifiedb ye xperiments,followed by adiscussiono fits application in the discovery of new type II CDK8 ligands. As ac onclusion, we explain the implication of this novel methoda sag eneral tool in the drug discoveryf ield. [22] and their corresponding availableP DB IDs, experimental free energies (DG exp ), and the length of MD simulations. 
Results and Discussion
Analysis of the binding thermodynamics of reference complexes
Overall analysis of bindingfree energiesa nd conformations
Computed and measuredb inding free energies for the reference CDK8 pyrazolourea ligandsa re compared and plottedi n Figure 2 , and the corresponding free-energy componentsa re presented in Table 2 . The free-energy convergencep lots can be found in Supporting Information (SI) FigureS1. As ignificant correlation is observed, as indicated by the correlationc oeffi-cient of 0.71, which is similart ot hose obtainedf or other protein-ligands ystemsv ia the VM2 method. [28, 29] According to the free-energy components in Ta ble 2, it appearst hat the major driving force for the binding of all the reference ligandsa re van der Waalsi nteractions. Pyrazolourea ligand 6h as the least van der Waals interaction with the protein. As ar esult, its calculated DG value is À6.45 kcal, which is equivalent to 20 mm, consistentw ith the experimental result of no binding. The overall electrostatic interactions (Coulomb + desolvation) provide an egative contribution to binding. The entropy penalties correctly reflect the flexibility of the ligands. For example, the variable substituents are linear and become longero np yrazolourea ligands6 ,7 ,8 ,3 ,9 ,1 0, 11,a nd their entropy penalties become larger in the same order.T he same phenomenoni s also observedo np yrazoloureal igands 4a nd 5. Notably,p yra- www.chemmedchem.org zolourea ligands 1a nd 2h ave the strongestb inding affinities with CDK8 among the 11 pyrazolourea ligands, but pay aboveaverage entropy penalties. Figure 3p rovides as ense for the conformational variation among the 11 bound pyrazolourea ligandst hrough an overlay of their most stable predicted conformations. The common scaffold that occupies the region called "deep pocket"t akes a uniform pose, while,n ot surprisingly,t he variable substituents that occupy the region called "front pocket" show aw ider range of positions. TheR MSDs for all the mobile atoms (i.e., mobile protein atoms plus ligand atoms) are quite similar and all < 2.0 ,i ndicating ag ood match between the predicted poses and the crystal structures. Ligand 1has the lowest RMSD for all the mobile atoms, presumably because we used the protein in PDB ID 4F6W,w hich is the co-crystal structure of the protein and ligand 1, in the VM2 calculations for all the pyrazolourea ligands while the RMSD was calculated between a ligand together with the protein and its availablec rystal structure. The ligands with RMSDs of < 1.0 for ligand alone have nearly identicalp oses as their crystal structures. For the ligands with larger RMSDs for ligand alone, ap ortiono ft heir structures deviate from the crystal structures. Ligand 5h as the largest RMSD for ligand alone, because in the predicted pose its morpholine moiety movesa way from A100 and thus loses the hydrogen bonding with this residue. Similarly,t he morpholine ring in pyrazolourea ligand 4d eviates from its crystal counterpart as well. For ligand 1, it is the piperazine ring that hasa large deviation.
Because our free-energy calculation shows that the binding is mainly driven by van der Waals interaction, and ligand sizes have strong correlation with van der Waals interactions, we plottedt he relationship between ligand sizes (i.e.,t he number of non-hydrogen atoms) and the experimental free energies to check how wellt hey correlate. Many scoring functions use ligand sizes to assess ligands. [30] The plot can be found in the Supporting Information (SIF igure S2). The correlation coefficient is 0.48, far below the correlation coefficient of 0.71 between the experimental and calculated free energies. Interestingly,t he data points on the plot have very similar distribution as those in Figure 2 . Thisr esult suggests that the molecular size is not the only key determinant of binding, and even for the congeneric ligand series, the drivingf orce of whichi s van der Waals interaction, other factors are still important to rank ligands accurately.I ti st hus of interest to examine the relationship between DH,w hich includes not only van der Waals, but also all other energy terms except entropy,a nd the experimentalf ree energies. The resulting correlation coefficient is improvedt o0 .61, and again the data points on the plot have a very similard istribution as those on the two above-mentioned plots (see FigureS3).T he new correlation coefficient is lower than that for the full computed free energies (0.71) by 15 %, echoingt he results in the previous studies. [28, 29] This result highlightst he importance of the configurational entropyt o the correlation between calculation and experiment.
We calculated the MM/PBSA energies for pyrazolourea ligands 1, 2, 5, 10, and 11 with the trajectories from the previous study, [31] and plottedt he relationship between the MM/PBSA energies and the experimental free energies as well ( Figure S4 ). The correlation coefficient is poor (0.4), much worse than the correlation coefficient of 0.72 when only the same five ligands are considered in the VM2 plot. The MM/PBSA method is also an end-pointm ethod that uses af orce-field and an implicit solventm odel to estimate binding free energies. Ak ey difference from the VM2 method is that MM/PBSA calculations typically either neglect configurationale ntropyo ra pproximate it as average vibrational entropyover essentially randomly selected, energy-minimized MD snapshots. Furthermore,t he MM/ PBSA method samples conformations by MD, which is far less thorought han the aggressive conformational searches in the VM2 method. It is thus not surprising that the MM/PBSA method performed much worse than the VM2 method. Figure 4p resents the major interactions in the predicted conformation of CDK8 and pyrazolourea ligand 1. ResiduesE 66 and D173 form strongh ydrogen bonds with the urea linker on 1, and K52 forms as alt bridgew ith E66. R356 has ac ation-p interaction with the benzene ring on 1. All of these interactions can be found in the crystal structure 4F6W as well. Ligand 1h as strong van der Waals interaction with the protein.
Close-upanalysis of selected reference complexes
The free-energy decomposition result (see Ta ble S1) shows that residues E66, L70, A172, D173, M174,a nd R356c ontribute the most to van der Waals energy.L igand 1p ays the largeste ntropy penalty among the reference ligands, presumably due to its large yet relatively flexible structure. In addition, ligand 1p ays am uch larger desolvation penalty than other ligands, but its Columbic energy is only on the average level, resulting in the pooresto verall electrostatic energy. This indicates that many polar groups on ligand 1don ot contribute to binding.
Pyrazolourea ligand 2h as as imilar bindingm ode as ligand 1, except for the cation-p interaction with R356. Instead, its tert-butyl group interacts with R356 throughv an der Waals interaction. Schneider et al. thought this interaction plays an important role in the binding of ligand 2. [22] However,a ccording to the free-energy decomposition result, residues E66, L70, I79, D173, and M174 contribute the largestv an der Waals energy to binding. The contribution from R356 is relatively small. Our calculation shows that the high affinity of ligand 2c omesf rom the well-balanced energy and entropyt erms. It has the second-largest molecular size and favorable van der Waals energy;i tp ays ar elatively small entropyp enalty;i ts desolvation penalty is much smaller than that of ligand 1a nd on the same level as those of other strong binderssuch as pyrazolourea ligands 5, 10 and 11.
As discussed in the subsection above, pyrazolourea ligand 5 has the largest RMSD forl igand alone among all the reference ligands. In the most stable predicted conformation, the morpholine ring loses the hydrogen bondingi nteraction with A100 which is assumed to be important for the binding of ligand 5t oC DK8. [22] As ar esult, its calculated Coulombic interaction is relatively small, which causes underestimation of its computed binding free energy.T he MD simulation did not catch this hydrogen bonding interaction either.I ti sp ossible that the parameters of the generalized Amber force field (GAFF)f or morpholine need to be adjusted to pick up this hydrogen bonding. The major van der Waals contributors to ligand 5a re E66, L70, I79, F97, and D173, yet the total van der Waals energy is much weaker than those of ligands 1a nd 2.
The VM2 method accurately predicted the binding pose of pyrazolourea ligand 11.I ts RMSD for ligand alone is the smallest among the reference ligands. Its hydroxy group forms strong hydrogen bondingi nteractions with D98 and A100. Probably for this reasoni ta chieves the strongest Coulombic energy and the most favorable overall electrostatice nergy.I ts van der Waals interaction is much smaller than those of other strong bindersh owever,a nd it pays al arge entropic penalty due to its long and flexible carbon chain. Therefore, Coulombic energy plays an important role in the binding of ligand 11 to CDK8. It has the optimal carbon chain length that assists strong binding to occur,relative to ligands 3, 9and 10.
Key information from the computational binding thermodynamicsstudy
The VM2m ethod predicted the binding free energiesw ith relatively high correlation to the experimental data for the pyrazoloureal igands. It also revealed information that is not available from experiments. The driving force for the binding of the reference ligands to CDK8/CycC is van der Waals interaction, and the overall electrostatic interaction has an egative contribution to the binding affinity.A nalysis of the strong binders suggestst hat there is room for all of them to improve their bindinga ffinities. Specifically, ligand 1p ays extremelyl arge desolvation ande ntropyp enalties. This can be improved by making the structure less flexible and positioning the polar groups at places that promoteh ydrogen bonding. Ligands 2 and 5h ave poor overall electrostatic energy.P olar groups can be introduced to form hydrogen bonding with the protein to improvet he electrostatic energy.L igand 11 pays al arge entropy penalty.I ts linear carbon chain can be modified to am ore rigid structure to decreaset he entropy penalty.
On the predicted lowest-energy conformations of all the reference ligands, the urea moiety undergoes hydrogenb onding with residues E66 and D173, and accounts for the majority of hydrogen bondingb etween the protein and the ligands. The 500 ns MD simulations [31] show that these hydrogen bonds are highly stable. Their occurrence percentages are roughly9 0-96 %a nd 76-93%,r espectively,f or all the reference ligands. Therefore, we used the urea moiety to initiate our virtual screening research for new type II CDK8 ligands.
Substructure-based virtual screening
As the first step, the urea moiety was used in the substructure search on the ChemDiv database. This resulted in 187 000 compounds. These compounds were screened with the criteria detailed in experimental sectioni ncluding am oiety-specific requirement: each nitrogen atom of the urea moiety must have one attached hydrogena tom. These hydrogen atoms are neededi nh ydrogen bondingw ith E66. After this initial screening step, the pool of candidates is decreased to 9914 compounds.
The reduced pool was then processed with the superposition and single-point energy evaluation method (see Experimental Section). It took5 -10 min to process one compound on one core CPU with aX eon E5-2640v 2o perating at 2.00 GHz. With 20 cores, we finished this energy-evaluation step in two days. The binding energies of the top-100 compounds are listed in Ta ble S2, and the molecular structures of the top-20 compounds are listedi nT able S3. Top-20 compounds have highly diverse molecular structures.W ea lso applied this evaluation method on ligand 1, and found it has a lower binding energyt han all of the candidates. After superposition and energy minimization, all of them were found to have as imilarb inding mode as that of pyrazolourea ligand 1. Figure5 presentst he conformations of pyrazolourea ligand 1 and the compound ranked #1 (hereafter referred to as CL1) by the superposition ands ingle-point energy evaluation method. ChemMedChem 2019, 14,107 -118 www.chemmedchem.org
The predicted conformationo fp yrazolourea ligand 1c an be alignedw ith the crystal structure 4F6W very well. For CL1, besides the key interactions with E66 and D173, it also forms a hydrogen bond with A100, ar esidue in the hinge region that is important for ligand binding and residence time. [22] The predicted conformationso fC L2, CL3, CL4, and CL5 with CDK8 are demonstrated in Figure S5 . CL2 and CL4 have the same binding mode as CL1, interacting with E66, D173, and A100 through hydrogen bonds.C L3 does not interactw ith A100, but its 1,3,4-thiadiazole forms hydrogen bonds with K52. CL5 does not have contact with A100 either;i nstead, its indole ring forms another hydrogen bond with D173.
We picked 19 compounds from the top-ranked group by the superpositiona nd single-point energy evaluation method, plus two selection rules:1 )candidates are able to form at least one hydrogen bond with the hinge region (residues 97-100), and 2) candidates do not have toxic substructures. We visually inspected the predicted conformations of the top compounds until the pool was filled. Table 3l ists the molecular structures of the candidates. When comparedw ith the top-20c ompounds ranked by the superposition and single-point energy evaluation method, the 19 candidates for VM2 evaluation are more similar to each other.F or instance, CL1 and CL2 differ by only one atom;CL4, CL21, CL37, and CL79 share the same scaffold. Similarly,C L34 and CL119, CL36, CL46 and CL83, CL125 and CL128 belong to three different congeneric series. The VM2 free-energy calculation took3 -7 days per compound on four CPU cores as described above.
Ta ble 4l ists the calculated binding free energies (DG)a nd their energy components of the 19 candidates. Only eight candidates have negative DG values, and none of them have DG valuesl ower than that of ligand 1. Some candidates have a large valence energy term whichi ncludesa ll the bonded interactions.T his indicates that these compounds have much internal stress at the protein binding site. This energy term can be considered as an indicator of how well ac ompound can fit the binding site. The candidates with positive DG pay al arge desolvation penalty,a nd their overall electrostatic energies are consistently > 30.0 kcal mol À1 ,a bout 10.0 kcal mol À1 higher than those of the candidates with negative DG. CL1 and CL2 were also ranked as the top-twoc ompounds by VM2. Relative to ligand 1, they have much higher( less favorable) DE vdW values, presumably due to their smaller molecular sizes, but they pay al ower entropic penaltya nd gain much lower (more favorable) DE Coulomb .CL88 was ranked third by VM2. Its Coulombic energy is on the same level as that of ligand 1, and its van der Waals contribution is similar to that of CL1 andC L2. It has ad ecreased desolvationp enalty and entropyp enalty that boost its calculated binding free energy.
The lowest-energy conformation of CL1 with CDK8 ( Figure 6 ) predicted by VM2 is similar to that predicted by the superposition and single-point energy evaluation method. The key hydrogen bonds with E66, D173, and A100 are well kept. Furthermore,i ts 1,3,4-thiadiazole formsh ydrogen bonds with K52. This may explain its highly favorable Coulombic contribution. CL1 features al arge aromatic scaffold, which makes the whole molecular structure relatively rigid and decreases the entropy penalty.T he extended conformation helps the bulky aromatic rings on both ends stay at the hydrophobic deep pocket and front pocket, respectively.T hey are surrounded by nonpolar residues and make extensive van der Waals interactions with them.C L1 has ar elatively low molecular weight of 473 Da. As ac omparison, the molecular weight of ligand 1i s640 Da. CL2 is different from CL1 by only one atom, and it has the exact same bindingm ode as CL1. The predicted lowest-energy conformation of CL88 can be found in Figure S6 . The starting conformation of CL88 for the VM2 free-energy calculation has hydrogen bonds with A100. But VM2 ended up with the morpholine ring rotatingb y9 0 8 and losing contactw ith A100. CL88 has ab ulky quinoline ring in the middle of its backbone. This helps decrease its entropy penalty,b ut also limits the arrangement of the whole molecular structure to accommodate hydrogen bonding between the morpholine ring and A100.
Among the 19 compounds evaluated with VM2, only the top-three compounds, that is, CL1, CL2 and CL88, kept their startingp oses, i.e.,t he key urea moiety had the expected contacts with CDK8, while the rest lost such contacts in their predicted lowest-energy conformations. In this study we focused on finding actives with our virtual screening tool. Therefore, we only purchased the top-three compounds ranked by VM2, and had bioassay testing with them. The result (DG exp )c an be found in Ta ble 4. CL1 and CL2 show strongb inding affinities with CDK8, the K d values of which are 42.5 and 114nm,r espectively.T he K d value of CL88 is 11.4 mm,w hich is barely lower than the no-binding cutoff (20 mm)i nt he test. Both the superpositiona nd single-point energy evaluation method and the VM2 methodr anked the three compounds correctly.C L1 achieved ab inding affinity similar to those of the two most potent reference ligands( K d values of 10 and 30 nm for ligands 2a nd 1, respectively). It has ad rug-like structure with dimethylxanthine, 1,3,4-thiadiazole, and benzene moieties on its backbone. Figure 2p resents the correlation between the calculated and experimental free energies when the data points of the three tested compounds are plotted together with the ref-erence ligands. The correlation coefficient drops from 0.71 to 0.47 after these data points are added. The poorer correlation is mainly caused by the overestimated bindingf ree energy of CL88. If this data point is removed from the plot, the correlation coefficient becomes 0.72. Despite the overestimation,V M2 predicts that CL88 has no contact with the hinge region, which is probably correct and explains the lowa ffinity of this compound. The interaction with the hinge region is important for CDK8 ligand binding and is found in the binding mode of the two strong binders, CL1 and CL2. With our substructure-based virtuals creeningp rotocol, we successfully discovered an ew potent CDK8/CycC typeIIl igand, CL1, which is comparable in affinity to the publishedr eference ligands. The effectivenesso fthis novel method originates from the combination of two powerful computational methods and the knowledge learned from the thermodynamics analysiso n reference ligands. The superposition and single-point energy evaluation methodw as able to efficiently estimate the binding poses for candidate compounds with ac o-crystal structure as reference. The bindinge nergies obtained by this method are based on force-field energy equations and the Poisson-Boltzmann (PB) solvation model. Energy minimization is implemented on candidate compounds and binding site residues until convergence. Therefore, this methodc an offer high accuracy in energy predictionw hilem aintaining relativelyh igh speed. The VM2 free-energy calculation method carrieso ut thorough conformation sampling and considersb othe nthalpy and entropy contributions to free energies. This methodi sf ast and accurate enough to be used as the last check point in virtual screening. And because it provides not only the total free energy and its components but also the energy contributions from the portionso ft he molecular systems, it is au seful tool for ligand optimization as well.
This novel substructure-based drug screening tool is also valuable in the contexto ff ragment-based drug discovery.T he Figure 6 . Predicted lowest-energy conformation of CL1 with CDK8 by VM2. ChemMedChem 2019, 14,107 -118 www.chemmedchem.org structural moieties that make key interactions with at arget protein in existing co-crystal structures can be used separately in similarity or substructure database searchesf or fragments, which can then be merged or linked together to generate new ligands. Fragments generallyh ave low affinities fort arget proteins and pose significant challenges for screeningt hrough biophysical techniques. [32, 33] The two energy evaluation methods in the virtual screening tool have the accuracy to solve this problemo ffragment screening.
Conclusions
We developedanovel virtuals creening method and applied it to the discovery of new CDK8/CycC type II ligands. The core of this method consists of two energy evaluation methods:s uperposition and single-pointe nergy evaluation, and VM2 freeenergy calculation. To gether,they are able to efficiently and accuratelys creen candidate compounds. In this research we first analyzed binding free energies and the energy components of 11 reference CDK8/CycC type II ligands with VM2, and extracted the information which provedh elpful for virtuals creening. The VM2 method accurately predicted the binding modes for the reference ligands, and the RMSDs were all < 2.0 for the ligand atoms and atoms of binding site residues. The correlationc oefficient is 0.71 between the calculated and measured free energies. The free-energy and MD calculations successfully revealed the factors that playi mportantr oles in the ligand binding with CDK8 DMG-outc onformation.T he overall driving force of the binding are van der Waals interactions, but for some ligands, Coulombic energy is also important to make binding occur.T he urea moiety contributes the majority of hydrogen bonding between the reference ligands and CDK8 and acts as the anchor to stabilize the ligands. Analysis of the strong binders also suggests that there is room fora ll of them to improve their binding affinities.
Startingw ith the urea moiety,w ei mplementedt he virtual screening method and singled out three compounds forb ioassay testing. The ranking from the experimental result is completely consistent with the predicted rankings by both the superposition and single-point energy evaluationm ethod and the VM2 free-energy calculation method. We successfully discoveredanew potent drug-like compound with a K d value of 42.5 nm.I nterestingly,t he top-two compoundsa re different by only one atom, but have an early threefold difference in binding affinity.T his was accurately predicted by both energy evaluation methods. Therefore, our novel virtual screening method is accurate and efficient enough to be used in drug design projects.W eb elieve this work has significant impact on the field of drug discovery.
Experimental Section

ReferenceCDK8-ligand complexes
Among the 11 ligands published by Schneider et al., [22] shown in Ta ble 1, seven have co-crystal structures with the CDK8 DMG-out conformation. The PDB IDs are 4F6W,4 F7L, 4F7J, 4F70, 4F6U, 4F6S, and 4F7N for ligands 1, 2, 3, 4, 5, 7, and 11,respectively.T he crystal structure 4F6W was used in all of the energy computations in this work because ligand 1i nt his crystal structure has the most extensive interactions with the protein and is one of the most potent ligands in this congeneric series. Ligand 1w as also used as the reference ligand in this study for comparison purposes.
Methodologies to investigate the binding thermodynamics of reference complexes
Free-energy calculation:Ar igorous statistical thermodynamics method, called VM2, [28] was used to calculate the binding free energies of CDK8 and its ligands in silico. VM2 belongs to ac lass of methods that focus on the most stable conformations of the molecules, so they are sometimes called predominant states methods. They compute the standard chemical potential of the proteinligand complex and of the free ligand and protein, and take the difference to obtain the standard free energy of binding [Eq. (1)]:
The standard chemical potential of each molecular species (i.e., complex, protein, and ligand) is obtained by finding its N most stable conformations (j = 1, N), integrating the Boltzmann factor within each energy well j to obtain al ocal configurational integral Z j ,a nd combining these local configuration integrals according to the following formula, where X = complex, protein, or ligand [Eq.
(2)]:
Here C 0 is the standard concentration, which, combined with the factor of 8p 2 ,a ccounts for the positional and orientational mobility of the free molecule at standard concentration, and the second form of the summation is given in terms of the chemical potentials of the individual conformations. The probability of energy well j can be approximated on the basis of Z j ,a nd thus the mean potential energy hUi or solvation energy hWi can be obtained. The configurational entropy at standard concentration can be computed as ÀTS o config ¼ G o À hU þ Wi.T he configurational entropy includes both ac onformational part, which reflects the number of energy wells (conformations), and av ibrational part, which reflects the average width of the energy wells. hU + Wi implicitly includes the change in solvent entropy via the implicit solvent model. As ac onsequence, the configurational entropy values reported here should not be directly compared with experimental entropy changes of binding for these systems.
The VM2 calculations are moderately fast, in part because they use implicit solvent models, which are widely accepted as computationally efficient alternatives to more detailed solvent models, and in part because for large systems such as protein-ligand complexes only as ubset of atoms ( % 500-5000, depending on the nature of the active site) are treated as mobile. The free energies calculated with VM2 are regarded as relative free energies instead of absolute free energies. They,t ogether with the energetic components, are used to rank the candidate ligands and analyze their binding modes. The quality of the calculated free energies can be judged through the Pearson correlation coefficient (R 2 )b etween DG calc and DG exp .
Crystal structure 4F6W was used as ar eference structure for VM2 free-energy calculations for all of the complexes of CDK8 and the ChemMedChem 2019, 14,107 -118 www.chemmedchem.org ligands in this study.T he starting conformations of the ligands were generated by superimposing them onto ligand 1i nPDB ID 4F6W.B ecause 4F6W misses residues 178-195, which form the main portion of the activation loop, ah omology model was generated by SWISS_MODEL [34] [35] [36] to add the missing residues. The pdb file for the homology model is provided in the Supporting Information. The addition of the missing residues is very important to our calculations for two reasons:1 )Without them the activation loop is broken, so its movement in calculation cannot reflect reality;and 2) because the missing residues are in the periphery of the binding site of CDK8 and some are very close to ligands, they have significant contribution to free energies. Amber99SB and generalized Amber force field (GAFF) [37] [38] [39] were applied to CDK8 and the ligands, respectively.T he Amber 14 package [40] [41] [42] was used to assign partial charges (Àbcc) to the ligands, and the partial charges for the protein were from the standard force-field parameters. The live set-the set of binding-site atoms treated as mobile-was defined as all atoms within 7 of any atom of the ligands. The real setthe set of protein atoms treated as rigid and thus supporting the live set-comprised all protein residues having any atom within 5 of any live-set atom. The pdb files for the live set and real set can be found in the Supporting Information. All other protein residues (totaling 194 out of 359 residues, or 54 %) were deleted to decrease the size of the non-bonded pair list and thus speed up the calculations. The interactions between atoms that are > 12 apart are negligible;t herefore those 194 residues have little contribution to free energies and thus can be deleted or ignored. To diminish any initial stress in the starting conformations that might artifactually drive the binding site away from its crystallographic starting conformation, the protein models were subjected to an initial relaxation. van der Waals radii were used in both generalized Born (GB) and PB solvation energy calculations. The VM2 method runs cycles of conformational search and configurational integration until convergence criteria are met. [28] Unbiased molecular dynamics (MD) simulation:W eu sed the trajectories from the previous study [31] to calculate MM/PBSA energies with the Amber 14 package [40] [41] [42] and analyze hydrogen bonding. The details of MD simulations can be found in the Supporting Information. We performed hydrogen bonding (H-bonding) analysis on the MD trajectories. In this study ah ydrogen bond (D < C-> H···A, where Da nd As tand for donor and acceptor,r espectively) is considered formed if the distance between Ha nd Ai s< 2.5 ,a nd the angle of D < C-> H···A is > 1508.W eu sed an in-house script to scan the trajectories for direct H-bonding between ligands and CDK8. H-bonding between ligands and the same residues are merged into one residue-ligand H-bonding formation. The occurrence percentage of ah ydrogen bond is calculated as the number of frames in which the hydrogen bond is found divided by the total number of frames (i.e.,2 5000).
Substructure-based virtualscreening
We developed an ovel substructure-based virtual screening method to assist the discovery of new drug candidates through efficient and extensive database searches. The workflow of this method is presented in Figure 1 . We first computationally study the binding thermodynamics of the existing protein-ligand complexes involving the target protein based on their co-crystal structures. The key moieties on the ligands that make critical contributions to protein binding are identified. Those moieties and their similar structures are used in substructure database searches. In this study the database we used was ChemDiv,w hich has ac ollection of over 1700 000 lead-like, drug-like small molecules in phar-maceutical industry. [43] The compounds obtained after the substructure database searches are then screened with the following criteria: 1) No more than five hydrogen bond donors, 2) No more than ten hydrogen bond acceptors, 3) Molecular mass < 600 Da and > 160 Da, 4) Octanol/water partition coefficient (logP) < 5a nd > À0.4, 5) Specific requirements on the key moieties.
These criteria can be viewed as am odified version of Lipinski's rule of five. [44, 45] The compounds that pass this initial screen are then evaluated and ranked by the superposition and single-point energy evaluation method, which is detailed below.T he top-20 to 30 compounds from this step are further analyzed with the VM2 free-energy calculation method, as described above. The top compounds that have similar or better binding free energies than areference ligand based on the VM2 evaluation are purchased (or synthesized), and tested by bioassay to verify the predicted binding affinities.
Superposition and single-point energy evaluation:O ur novel superposition method is able to quickly generate the correct conformations for candidate compounds at the binding site of at arget protein. It does not apply conformational searches on candidate compounds. Instead, for the compounds from substructural searches, superposition is implemented by aligning the substructure of a candidate compound and ar eference ligand at its bound state in a co-crystal structure. This method is based on the assumption that the substructure provides the key interactions between the target protein and the ligands. Therefore, as long as we anchor the key substructure at the correct position and pose, the whole ligand would probably have the correct bound conformation as well. The information about the key substructure is extracted from analysis of the existing ligands of the target protein. Our superposition method also works on the compounds from similarity searches. In this case, our method first finds the common part, which can be backbones, moieties or functional groups, between ac andidate compound and ar eference ligand, and then superimposes them based on the common part. In the case that there are more than one key substructure or common part, superposition is implemented one at at ime;i fasubstructure or common part is symmetric, the candidate compound is rotated to generate all possible superimposed conformations. In this study ligand 1i nt he crystal structure 4F6W was used as the reference ligand.
After ac andidate compound is placed into the binding site of a target protein with possibly multiple conformations, these conformations of the candidate compound together with the target protein are then energy minimized using the Amber 14 package until convergence. A live set is defined similarly as in the VM2 method. Only the compound atoms and the protein atoms in the live set are relaxed in energy minimization. The energy of the complex E complex is calculated with Equation (3):
where E el and E vdW are electrostatic and van der Waals energy with parameters of Amber99SB for the protein and GAFF for the ligands; G PB is the solvation energy computed by solving the Poisson-Boltzmann (PB) equation; [46, 47] and G np is the nonpolar energy estimated from solvent-accessible surface area. ChemMedChem 2019, 14,107 -118 www.chemmedchem.org
The protein and candidate compound are then separated from the complex, but their conformations are kept fixed. Their energies, E protein and E ligand ,a re calculated by Equation (3) as well. The binding energy for the compound is then calculated as per Equation (4):
Theoretically,t his superposition and single-point energy evaluation method is faster and more accurate than the conventional docking and scoring method for the following reasons:F irst, the binding conformations of the candidate molecules are obtained by direct superposition to the available crystal structure of ar eference molecule. It therefore saves the time of generating millions of random conformations as the general practice in docking, and still has a more accurate binding mode with the protein. Second, the binding energy includes the solvation energy,a nd is calculated with forcefield-based energy equations and the PBSA model, thus making more physical sense than scoring functions. Therefore, it is quite accurate and efficient for screening al arge number of candidates. However,t his method does not include an entropy contribution and only accounts for the energy contribution from as ingle conformation. The top compounds obtained from this method must be further analyzed and ranked using the more accurate VM2 freeenergy calculation method.
Compounds and bioassay
In this study the compounds selected for bioassay testing were purchased from ChemDiv Inc. Bioassay testing was conducted by Proteros biostructures GmbH. [48] The Proteros Reporter Displacement Assay was used to determine K d values. Briefly,t he Proteros reporter displacement assay is based on reporter probes that are designed to bind to the site of interest of the target protein. The proximity between reporter and protein results in the emission of an optical signal. Compounds that bind to the same site as the reporter probe displace the probe, causing signal diminution. Reporter displacement is measured over time after the addition of compounds at various concentrations. To ensure that the rate of probe displacement reflects compound binding and not probe dissociation, probes are designed to have high dissociation rates. Thus, compound binding and not probe dissociation is the ratelimiting step of probe displacement. For K d determination, percent probe displacement values are calculated for the final time point, at which the system has reached equilibrium. For each compound concentration, percent probe displacement values are calculated and plotted against the compound concentration.
